SCHEMBL5336615

SCHEMBL5336615

CC(C)(C)OC(=O)N1CCN(c2cccc(Cl)c2C#N)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
GAA P10253 1/20 0.56
STS P08842 1/20 0.47
MAPK8 P45983 1/20 0.47
POLB P06746 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
MAPT P10636 2/20 0.44
LMNA P02545 2/20 0.44
KCNH2 Q12809 1/20 0.44
GPR119 Q8TDV5 2/20 0.43
TP53 P04637 1/20 0.43
NOTUM Q6P988 1/20 0.43
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2165432 0.85 KDM4E (0.54) ALDH1A1KDM4EMAPTLMNAKCNH2
SCHEMBL4613647 0.85 SMARCA2 (0.50) ALDH1A1GAAMAPTLMNAKCNH2
SCHEMBL5683482 0.84 THRB (0.48) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL14852499 0.84 MEN1 (0.56) ALDH1A1GAASTSMAPK8POLB
SCHEMBL30208139 0.84 MEN1 (0.56) ALDH1A1GAASTSMAPK8POLB
SCHEMBL4615741 0.84 NPSR1 (0.53) ALDH1A1MAPK8POLBLMNA
SCHEMBL246696 0.83 DRD2 (0.56) ALDH1A1STSMAPK8POLBMEN1
SCHEMBL25003057 0.83 NR1H2 (0.47) ALDH1A1STSMAPK8POLBMEN1
SCHEMBL21996003 0.82 LMNA (0.56) ALDH1A1STSMAPK8POLBMEN1
SCHEMBL27237940 0.82 KDM4E (0.66) ALDH1A1KDM4EL3MBTL1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHUJING BIOPHARMA CO., LTD (CN) 2024-11-07 US disclosed
CN-117769545-A Tri-fused ring derivative-containing regulator, preparation method and application thereof 上海枢境生物科技有限公司 2024-03-26 CN disclosed
WO-2023011608-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海枢境生物科技有限公司 2023-02-09 WO disclosed
WO-2023011608-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海枢境生物科技有限公司 2023-02-09 WO disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TPH1, TPH2, GAP43 ALDH1A1 2405/4885KDM4E 4291/4885L3MBTL1 4406/4885
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R ALDH1A1 1055/4885KDM4E 2886/4885L3MBTL1 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.